Lilly v. IPPI
Executive Summary
Lilly v. IPPI: Oncovin-manufacturer Lilly met with FDA to discuss agency approval of International Pharmaceutical Products Inc.'s vincristine. According to an agency memo of the meeting, Lilly's Washington counsel urged FDA to rescind approval of the generic anticancer agent on the grounds that IPPI still had not satisfied patent certification and notification requirements. FDA previously rescinded approval of IPPI's ANDA for vincristine until the generic company submitted Lilly patent information ("The Pink Sheet" Feb. 2, T&G-5). The memo reports that FDA Chief Counsel Thomas Scarlett replied "he was not prepared to recommend that IPPI's approval be rescinded a second time but that FDA will try to improve its procedures for handling patent filings and certifications".
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.